Clinical Trial Update: STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa [Phase 2]

View source ↗

Summary

Phase 2 trial of STI571 (imatinib) in patients with chronic myeloid leukemia that has not responded to interferon alfa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• STI571 (imatinib)

Snippet

Sponsor: Novartis | Conditions: Leukemia | Phase 2 | Status: COMPLETED